Morgan Stanley Seagen Inc. Transaction History

Morgan Stanley

  • $1.35 Trillion
  • Q3 2024

Shares

11 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q3 2023

Nov 15, 2023
BUY
$191.51 - $216.16 $49.9 Million - $56.4 Million
260,787 Added 35.51%
995,182 $211 Million
Q2 2023

Aug 14, 2023
BUY
$187.64 - $206.25 $9.4 Million - $10.3 Million
50,119 Added 7.32%
734,395 $141 Million
Q1 2023

May 15, 2023
SELL
$127.59 - $203.08 $5.6 Million - $8.91 Million
-43,876 Reduced 6.03%
684,276 $139 Million
Q4 2022

Feb 14, 2023
BUY
$117.37 - $139.17 $11.9 Million - $14.1 Million
101,477 Added 16.19%
728,152 $93.6 Million
Q3 2022

Nov 14, 2022
BUY
$135.27 - $180.11 $6.76 Million - $9 Million
49,983 Added 8.67%
626,675 $85.8 Million
Q2 2022

Oct 27, 2022
BUY
$108.81 - $179.33 $20.2 Million - $33.3 Million
185,755 Added 47.52%
576,692 $102 Million
Q2 2022

Aug 15, 2022
BUY
$108.81 - $179.33 $20.2 Million - $33.3 Million
185,755 Added 47.52%
576,692 $102 Million
Q1 2022

Oct 27, 2022
SELL
$119.61 - $157.85 $22.2 Million - $29.3 Million
-185,755 Reduced 32.21%
390,937 $56.3 Million
Q1 2022

May 13, 2022
SELL
$119.61 - $157.85 $8.95 Million - $11.8 Million
-74,810 Reduced 16.06%
390,937 $56.3 Million
Q4 2021

Feb 14, 2022
BUY
$142.57 - $190.86 $16.2 Million - $21.7 Million
113,709 Added 32.3%
465,747 $72 Million
Q3 2021

Nov 15, 2021
BUY
$142.45 - $169.82 $50.1 Million - $59.8 Million
352,038 New
352,038 $59.8 Million

Others Institutions Holding SGEN

# of Institutions
39
Shares Held
1.26M
Call Options Held
23K
Put Options Held
55.2K
View Full List

About Seagen Inc.

SGEN Quotes by TradingView
  • Ticker SGEN
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 185,664,992
  • Description
  • Seagen Inc., a biotechnology company, develops and commercializes therapies for the treatment of cancer in the United States and internationally. The company offers ADCETRIS, an antibody-drug conjugate (ADC) for the treatment of patients with Hodgkin lymphoma or CD30-positive T-cell lymphomas; PADCEV, an ADC targeting Nectin-4 for the treatment ...
More about SGEN
Track This Portfolio

Track Morgan Stanley Portfolio

Follow Morgan Stanley and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Morgan Stanley, based on Form 13F filings with the SEC.

News

Stay updated on Morgan Stanley with notifications on news.

Choose your preferred platform and Sign Up 👇 Telegram Email